title: Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms.
abstract: Pain is common among opioid-dependent patients, yet pharmacologic strategies are limited. The aim of this study was to explore whether escitalopram, a selective serotonin reuptake inhibitor, was associated with reductions in pain. The study used longitudinal data from a randomized, controlled trial that evaluated the effects of escitalopram on treatment retention in patients with depressive symptoms who were initiating buprenorphine/naloxone for treatment of opioid dependence. Participants were randomized to receive escitalopram 10 mg or placebo daily. Changes in pain severity, pain interference, and depression were assessed at 1-, 2-, and 3-month visits with the visual analog scale, Brief Pain Inventory, and the Beck Depression Inventory II, respectively. Fixed-effects estimators for panel regression models were used to assess the effects of intervention on changes in outcomes over time. Additional models were estimated to explore whether the intervention effect was mediated by within-person changes in depression. In this sample of 147 adults, we found that participants randomized to escitalopram had significantly larger reductions on both pain severity (b=-14.34, t=-2.66, P<.01) and pain interference (b=-1.20, t=-2.23, P<.05) between baseline and follow-up. After adjusting for within-subject changes in depression, the estimated effects of escitalopram on pain severity and pain interference were virtually identical to the unadjusted effects. This study of opioid-dependent patients with depressive symptoms found that treatment with escitalopram was associated with clinically meaningful reductions in pain severity and pain interference during the first 3 months of therapy.
authors.affiliation: Boston University School of Medicine/Boston Medical Center, 801 Massachusetts Ave, Boston MA 02118, USA Butler Hospital, 345 Blackstone Blvd, Providence, RI 02906, USA Warren Alpert School of Medicine at Brown University, Waterman Street, Providence, RI, 02912, USA.
authors.forename: Judith I
authors.initials: JI
authors.lastname: Tsui
authors.forename: Debra S
authors.initials: DS
authors.lastname: Herman
authors.forename: Malyna
authors.initials: M
authors.lastname: Kettavong
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Anderson
authors.forename: Michael D
authors.initials: MD
authors.lastname: Stein
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage*; D015283:Citalopram / Q000008:administration & dosage*; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000523:psychology; D010146:Pain / Q000188:drug therapy* / Q000523:psychology; D012720:Severity of Illness Index
chemical_list: D000701:Analgesics, Opioid; D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram